Short-term efficacy and safety of Brolucizumab for neovascular age-related macular degeneration in the Russian Federation-Reference-Cited by-同舟云学术

Short-term efficacy and safety of Brolucizumab for neovascular age-related macular degeneration in the Russian Federation

Published:2022 Issue:3 Volume:138 Page:55
ISSN:0042-465X
Container-title:Vestnik oftal'mologii
language:en
Short-container-title:Vestn. oftal'mol.

Author:

Kulikov A.N.^ORCID,Gazizova I.R.,Maltsev D.S.^ORCID,Malafeeva A.Yu.^ORCID,Vasilyev A.S.,Zhalimova V.R.

Publisher

Media Sphere Publishing Group

Subject

Ophthalmology

Reference9 articles.

1. Novartis Pharmaceuticals. Beovu 120 mg/ml solution for injection in pre-filled syringe — Summary of Product Characteristics. 2020. Accessed November 30, 2020. www.ema.europa.eu/en/documents/product-information/beovu-epar-product-information_en.pdf

2. Instructions for use of the medicinal product Visque (solution for intraocular administration), taking into account changes 1, 2. Registration certificate LP-006598 dated 11/24/2020 (reissued on 05/25/2021). (In Russ.)

3. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial

4. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

5. HAWK and HARRIER

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration;Russian Annals of Ophthalmology;2024

2. Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis;Clinical Ophthalmology;2023-09

3. Short-term experience of intravitreal brolucizumab in treatment of diabetic macular edema;Vestnik oftal'mologii;2023